Literature DB >> 28766207

Use of Sentinel Lymph Node Dissection After Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer at Diagnosis: Practice Patterns of American Society of Breast Surgeons Members.

Abigail S Caudle1, Isabelle Bedrosian2, Denái R Milton3, Sarah M DeSnyder2, Henry M Kuerer2, Kelly K Hunt2, Elizabeth A Mittendorf2.   

Abstract

BACKGROUND: The accuracy of sentinel lymph node dissection (SLND) in clinically node-positive patients who receive neoadjuvant chemotherapy has been investigated in clinical trials. This survey was designed to assess familiarity and impact of these trial findings into practice.
METHODS: American Society of Breast Surgeons members were invited by e-mail to complete an anonymous online survey. A total of 642 members responded (21% of 3090 eligible members). Results were summarized as proportions based on the number of responses to each question.
RESULTS: Respondents indicated knowledge of the Z1071 (86%), SENTINA (57%), and SN-FNAC (39%) trials. The published false negative rates (FNR) of the trials were correctly reported by 53% (336/638) of respondents. Before the trials, 45% (285/636) offered SLND compared with 85% (543/638) after the trials. In the 556 respondents who reported knowledge of at least one trial, 310 (56%) currently offer SLND to >50% of patients, 175 (31%) offer to <50%, and 70 (13%) routinely perform axillary lymph node dissection. Respondents who reported knowledge of the trials but did not change their practice to incorporate SLND (n = 67) cited concerns over lack of outcome data (64%), worries about FNR (42%), lack of resources (34%), or objections from radiation oncologists (25%), medical oncologists (18%), or other surgeons (8%).
CONCLUSIONS: The publication of trials evaluating SLND in clinically node-positive patients has resulted in changes in practice. Concerns over the FNR and lack of outcome data limit incorporation of SLND into practice by some surgeons.

Entities:  

Mesh:

Year:  2017        PMID: 28766207      PMCID: PMC5759951          DOI: 10.1245/s10434-017-5958-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  24 in total

1.  The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer.

Authors:  Rosalinda Alvarado; Min Yi; Huong Le-Petross; Michael Gilcrease; Elizabeth A Mittendorf; Isabelle Bedrosian; Rosa F Hwang; Abigail S Caudle; Gildy V Babiera; Jeri S Akins; Henry M Kuerer; Kelly K Hunt
Journal:  Ann Surg Oncol       Date:  2012-07-07       Impact factor: 5.344

2.  Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.

Authors:  H M Kuerer; A A Sahin; K K Hunt; L A Newman; T M Breslin; F C Ames; M I Ross; A U Buzdar; G N Hortobagyi; S E Singletary
Journal:  Ann Surg       Date:  1999-07       Impact factor: 12.969

3.  Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial.

Authors:  Abigail S Caudle; Wei T Yang; Elizabeth A Mittendorf; Daliah M Black; Rosa Hwang; Brian Hobbs; Kelly K Hunt; Savitri Krishnamurthy; Henry M Kuerer
Journal:  JAMA Surg       Date:  2015-02       Impact factor: 14.766

4.  Lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for stage II and III breast cancer.

Authors:  Glen C Balch; Suhail K Mithani; Ken R Richards; R Daniel Beauchamp; Mark C Kelley
Journal:  Ann Surg Oncol       Date:  2003-07       Impact factor: 5.344

5.  Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.

Authors:  Judy C Boughey; Vera J Suman; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Bret Taback; A Marilyn Leitch; Henry M Kuerer; Monet Bowling; Teresa S Flippo-Morton; David R Byrd; David W Ollila; Thomas B Julian; Sarah A McLaughlin; Linda McCall; W Fraser Symmans; Huong T Le-Petross; Bruce G Haffty; Thomas A Buchholz; Heidi Nelson; Kelly K Hunt
Journal:  JAMA       Date:  2013-10-09       Impact factor: 56.272

6.  Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation.

Authors:  Erika A Newman; Michael S Sabel; Alexis V Nees; Anne Schott; Kathleen M Diehl; Vincent M Cimmino; Alfred E Chang; Celina Kleer; Daniel F Hayes; Lisa A Newman
Journal:  Ann Surg Oncol       Date:  2007-05-19       Impact factor: 5.344

7.  Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance).

Authors:  Judy C Boughey; Karla V Ballman; Huong T Le-Petross; Linda M McCall; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Bret Taback; Eric C Feliberti; Kelly K Hunt
Journal:  Ann Surg       Date:  2016-04       Impact factor: 12.969

8.  Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study.

Authors:  Jean-Marc Classe; Virginie Bordes; Loic Campion; Herve Mignotte; François Dravet; Jean Leveque; Christine Sagan; Pierre François Dupre; Gilles Body; Sylvia Giard
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

9.  Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy.

Authors:  Laura S Dominici; Elizabeth A Mittendorf; Xumei Wang; Jun Liu; Henry M Kuerer; Kelly K Hunt; Abenaa Brewster; Gildy V Babiera; Thomas A Buchholz; Funda Meric-Bernstam; Isabelle Bedrosian
Journal:  Breast Cancer Res       Date:  2012-05-23       Impact factor: 6.466

10.  Are "breast-focused" surgeons more competent?

Authors:  Helen A Pass; Suzanne V Klimberg; Edward M Copeland
Journal:  Ann Surg Oncol       Date:  2008-02-05       Impact factor: 5.344

View more
  13 in total

1.  Omission of Axillary Lymph Node Dissection is Associated with Inferior Survival in Breast Cancer Patients with Residual N1 Nodal Disease Following Neoadjuvant Chemotherapy.

Authors:  Muayad F Almahariq; Ronald Levitin; Thomas J Quinn; Peter Y Chen; Nayana Dekhne; Sayee Kiran; Amita Desai; Pamela Benitez; Maha S Jawad; Gregory S Gustafson; Joshua T Dilworth
Journal:  Ann Surg Oncol       Date:  2020-07-25       Impact factor: 5.344

Review 2.  Breast cancer metastasis through the lympho-vascular system.

Authors:  S David Nathanson; David Krag; Henry M Kuerer; Lisa A Newman; Markus Brown; Dontscho Kerjaschki; Ethel R Pereira; Timothy P Padera
Journal:  Clin Exp Metastasis       Date:  2018-05-23       Impact factor: 5.150

3.  Is Nodal Clipping Beneficial for Node-Positive Breast Cancer Patients Receiving Neoadjuvant Chemotherapy?

Authors:  Giacomo Montagna; Minna K Lee; Varadan Sevilimedu; Andrea V Barrio; Monica Morrow
Journal:  Ann Surg Oncol       Date:  2022-07-28       Impact factor: 4.339

4.  Feasibility of fine-needle aspiration for assessing responses to chemotherapy in metastatic nodes marked with clips in breast cancer: A prospective registry study.

Authors:  Abigail S Caudle; Henry M Kuerer; Savitri Krishnamurthy; Kyungmin Shin; Brian P Hobbs; Junsheng Ma; Elizabeth A Mittendorf; Ashley C Washington; Sarah M DeSnyder; Dalliah M Black; Kelly K Hunt; Wei T Yang
Journal:  Cancer       Date:  2018-10-25       Impact factor: 6.860

5.  Selecting Node-Positive Patients for Axillary Downstaging with Neoadjuvant Chemotherapy.

Authors:  Giacomo Montagna; Anita Mamtani; Andrea Knezevic; Edi Brogi; Andrea V Barrio; Monica Morrow
Journal:  Ann Surg Oncol       Date:  2020-06-02       Impact factor: 5.344

6.  A New Model Incorporating Axillary Ultrasound After Neoadjuvant Chemotherapy to Predict Non-Sentinel Lymph Node Metastasis in Invasive Breast Cancer.

Authors:  Kai Zhang; Qian Zhu; Danli Sheng; Jiawei Li; Cai Chang
Journal:  Cancer Manag Res       Date:  2020-02-10       Impact factor: 3.989

7.  Predictors of Nodal Pathological Complete Response in Asian Women with Stage II-III Node-Positive Breast Cancer.

Authors:  Giacomo Montagna; Yiwei Tong; Mathilde Ritter; Jeremy Levi; Walter P Weber; Xiaosong Chen; Kunwei Shen
Journal:  Oncology       Date:  2021-03-18       Impact factor: 3.734

8.  Diagnostic Accuracy of Different Surgical Procedures for Axillary Staging After Neoadjuvant Systemic Therapy in Node-positive Breast Cancer: A Systematic Review and Meta-analysis.

Authors:  Janine M Simons; Thiemo J A van Nijnatten; Carmen C van der Pol; Ernest J T Luiten; Linetta B Koppert; Marjolein L Smidt
Journal:  Ann Surg       Date:  2019-03       Impact factor: 12.969

9.  Excision of both pretreatment marked positive nodes and sentinel nodes improves axillary staging after neoadjuvant systemic therapy in breast cancer.

Authors:  J M Simons; M L M A van Pelt; A W K S Marinelli; M E Straver; A M Zeillemaker; L M Pereira Arias-Bouda; T J A van Nijnatten; L B Koppert; K K Hunt; M L Smidt; E J T Luiten; C C van der Pol
Journal:  Br J Surg       Date:  2019-10-08       Impact factor: 6.939

10.  Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer.

Authors:  Sungchan Gwark; Sei Hyun Ahn; Woo Chul Noh; Eun Sook Lee; Yongsik Jung; Lee Su Kim; Wonshik Han; Seok Jin Nam; Gyungyub Gong; Seon-Ok Kim; Hee Jeong Kim
Journal:  Front Oncol       Date:  2021-07-02       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.